South Africa has a well-established pharmaceutical industry, and North Africa is attracting more attention from Western drugmakers. But many countries in between have limited infrastructure or challenging political situations. Figuring out which have the potential to be emerging markets worth investing in can be a challenge. Jordan-based Hikma sees potential in Ethiopia.
Despite the negative attention of the ongoing corruption probe, GlaxoSmithKline is still pressing ahead with its Chinese expansion plans, and its vaccine unit is a major part of the strategy.
Just a few months after Amgen execs lamented a big Asian gap in their global strategy, the Big Biotech company has joined hands with Astellas to set up a new joint venture in Japan. Amgen is contributing 5 experimental-stage programs to the JV, including their late-stage anti-PCSK9 program for the cholesterol drug AMG-145.
Saudi Arabia is drawing yet more interest from companies that see potential from manufacturing drugs there. The Indonesian company Pharmaniaga is teaming with Saudi Arabia-based Modern Healthcare Solutions to build a drug manufacturing plant.
After indefinitely suspending their plans over a Chinese regulatory snag, Sony and Olympus are finally kicking off their long-planned medical device joint venture, planning to sell endoscopes and imaging technologies around the world.
Bausch + Lomb said it will buy the remaining shares of ophthalmology laser company Technolas Perfect Vision, a company it initially established through a joint venture with 2010 Perfect Vision AG back in 2009.
Three years after Teva and Switzerland's Lonza joined forces to create a new joint venture to develop a few blockbuster biosimilars, one of their lead programs has hit an unexpected roadblock. The Israeli newspaper Haaretz reports that Teva has suspended its Phase III study of a biosimilar of Rituxan, one of the world's top-selling drugs from Roche.
The company has created a joint venture with Manipal Group in India to tap that market primarily for sales of its mobile monitoring devices.
After announcing the tie-up almost a year ago, India's Dr. Reddy's Laboratories ($RDY) finally expects to ink a joint venture agreement with Fujifilm.
GlaxoSmithKline ($GSK) and Daiichi Sankyo ($D4S.BE) will jointly invest about $1.2 million and pool their vaccine operations into a 50/50 joint venture that they expect will be largest vaccine company in Japan.